Form 4: Axogen's Chief Innovation Officer Reports Stock Transactions
SEC Form 4 Filing
Erick Wayne DeVinney, Axogen's Chief Innovation Officer, reports the acquisition and disposal of company stock related to performance stock units and tax obligations.
Summary
- On February 28, 2025, Erick Wayne DeVinney, Chief Innovation Officer of Axogen, Inc., acquired 24,799 shares of common stock due to the attainment of certain performance criteria.
- On March 4, 2025, DeVinney disposed of 8,296 shares to cover tax withholding obligations related to the vesting of performance stock units at a weighted average price of $18.35.
- Following these transactions, DeVinney beneficially owns 201,005 shares of Axogen common stock.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions by an officer, with no inherent positive or negative implications for the company's overall prospects.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- Shareholders are informed about insider transactions, promoting transparency.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Acquisition of 24,799 shares of common stock due to performance criteria. |
| 03/03/2025 | Deemed execution date for the acquisition of shares. |
| 03/04/2025 | Sale of 8,296 shares to cover tax withholding obligations. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.